Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Background. Littie is known about the incidence and evolution of proteinuria as a complication of sirolimus rescue in children. This study describes pediatric renal transplant (Tx) recipients who were treated with sirolimus and who developed heavy proteinuria. Risk factors for the development of proteinuria and its time course are explored. Methods. Data at various time points after sirolimus introduction were abstracted from the records of children treated at the author's center. The repeated measures general linear model and the Student's paired t test were used to analyze changes in laboratory values over time. Results. Of the 13 children on sirolimus, 12 developed heavy proteinuria after a mean interval of 1 month. The mean urine protein (Up)-to-creatinine (c) ratio increased from 1.1 to a peak value of 3.9 (P=0.003) at 4.6 months after the start of sirolimus. Although not statistically significant, children on no calcineurin inhibitor (CNI) had a greater increase in the Up/c than those on low-dose CNI. At last follow-up, with the use of angiotensin receptor blockers (ARB), the Up/c declined to 2.2. No predictors could be identified for the development of proteinuria. Conclusions. Heavy proteinuria is common after the use of sirolimus as rescue therapy in children with renal Tx. Whether this is attributable to a toxic effect of the sirolimus itself or to lower CNI exposure is uncertain. Early detection of proteinuria is important to enable prompt intervention. Most children have a reduction in their Up/c with the use of ARB and can therefore be continued on sirolimus.

Original languageEnglish (US)
Pages (from-to)1362-1366
Number of pages5
JournalTransplantation
Volume78
Issue number9
DOIs
StatePublished - Nov 15 2004

Fingerprint

Sirolimus
Proteinuria
Pediatrics
Kidney
Urine
Angiotensin Receptor Antagonists
Proteins
Transplant Recipients
Poisons
Linear Models
Creatinine
Students
Incidence
Calcineurin Inhibitors

Keywords

  • Chronic allograft nephropathy
  • Nephrotic syndrome
  • Pediatric
  • Proteinuria
  • Sirolimus

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. / Butani, Lavjay.

In: Transplantation, Vol. 78, No. 9, 15.11.2004, p. 1362-1366.

Research output: Contribution to journalArticle

@article{aa6cdfed55944a199cc2009ca4c4c8d4,
title = "Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue",
abstract = "Background. Littie is known about the incidence and evolution of proteinuria as a complication of sirolimus rescue in children. This study describes pediatric renal transplant (Tx) recipients who were treated with sirolimus and who developed heavy proteinuria. Risk factors for the development of proteinuria and its time course are explored. Methods. Data at various time points after sirolimus introduction were abstracted from the records of children treated at the author's center. The repeated measures general linear model and the Student's paired t test were used to analyze changes in laboratory values over time. Results. Of the 13 children on sirolimus, 12 developed heavy proteinuria after a mean interval of 1 month. The mean urine protein (Up)-to-creatinine (c) ratio increased from 1.1 to a peak value of 3.9 (P=0.003) at 4.6 months after the start of sirolimus. Although not statistically significant, children on no calcineurin inhibitor (CNI) had a greater increase in the Up/c than those on low-dose CNI. At last follow-up, with the use of angiotensin receptor blockers (ARB), the Up/c declined to 2.2. No predictors could be identified for the development of proteinuria. Conclusions. Heavy proteinuria is common after the use of sirolimus as rescue therapy in children with renal Tx. Whether this is attributable to a toxic effect of the sirolimus itself or to lower CNI exposure is uncertain. Early detection of proteinuria is important to enable prompt intervention. Most children have a reduction in their Up/c with the use of ARB and can therefore be continued on sirolimus.",
keywords = "Chronic allograft nephropathy, Nephrotic syndrome, Pediatric, Proteinuria, Sirolimus",
author = "Lavjay Butani",
year = "2004",
month = "11",
day = "15",
doi = "10.1097/01.TP.0000140868.88149.63",
language = "English (US)",
volume = "78",
pages = "1362--1366",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue

AU - Butani, Lavjay

PY - 2004/11/15

Y1 - 2004/11/15

N2 - Background. Littie is known about the incidence and evolution of proteinuria as a complication of sirolimus rescue in children. This study describes pediatric renal transplant (Tx) recipients who were treated with sirolimus and who developed heavy proteinuria. Risk factors for the development of proteinuria and its time course are explored. Methods. Data at various time points after sirolimus introduction were abstracted from the records of children treated at the author's center. The repeated measures general linear model and the Student's paired t test were used to analyze changes in laboratory values over time. Results. Of the 13 children on sirolimus, 12 developed heavy proteinuria after a mean interval of 1 month. The mean urine protein (Up)-to-creatinine (c) ratio increased from 1.1 to a peak value of 3.9 (P=0.003) at 4.6 months after the start of sirolimus. Although not statistically significant, children on no calcineurin inhibitor (CNI) had a greater increase in the Up/c than those on low-dose CNI. At last follow-up, with the use of angiotensin receptor blockers (ARB), the Up/c declined to 2.2. No predictors could be identified for the development of proteinuria. Conclusions. Heavy proteinuria is common after the use of sirolimus as rescue therapy in children with renal Tx. Whether this is attributable to a toxic effect of the sirolimus itself or to lower CNI exposure is uncertain. Early detection of proteinuria is important to enable prompt intervention. Most children have a reduction in their Up/c with the use of ARB and can therefore be continued on sirolimus.

AB - Background. Littie is known about the incidence and evolution of proteinuria as a complication of sirolimus rescue in children. This study describes pediatric renal transplant (Tx) recipients who were treated with sirolimus and who developed heavy proteinuria. Risk factors for the development of proteinuria and its time course are explored. Methods. Data at various time points after sirolimus introduction were abstracted from the records of children treated at the author's center. The repeated measures general linear model and the Student's paired t test were used to analyze changes in laboratory values over time. Results. Of the 13 children on sirolimus, 12 developed heavy proteinuria after a mean interval of 1 month. The mean urine protein (Up)-to-creatinine (c) ratio increased from 1.1 to a peak value of 3.9 (P=0.003) at 4.6 months after the start of sirolimus. Although not statistically significant, children on no calcineurin inhibitor (CNI) had a greater increase in the Up/c than those on low-dose CNI. At last follow-up, with the use of angiotensin receptor blockers (ARB), the Up/c declined to 2.2. No predictors could be identified for the development of proteinuria. Conclusions. Heavy proteinuria is common after the use of sirolimus as rescue therapy in children with renal Tx. Whether this is attributable to a toxic effect of the sirolimus itself or to lower CNI exposure is uncertain. Early detection of proteinuria is important to enable prompt intervention. Most children have a reduction in their Up/c with the use of ARB and can therefore be continued on sirolimus.

KW - Chronic allograft nephropathy

KW - Nephrotic syndrome

KW - Pediatric

KW - Proteinuria

KW - Sirolimus

UR - http://www.scopus.com/inward/record.url?scp=8644289235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8644289235&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000140868.88149.63

DO - 10.1097/01.TP.0000140868.88149.63

M3 - Article

C2 - 15548976

AN - SCOPUS:8644289235

VL - 78

SP - 1362

EP - 1366

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 9

ER -